Côd QR

Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study

Abstract Background Inflammatory breast cancer (IBC) is an aggressive and highly angiogenic disease. Eribulin is a microtubule inhibitor with anti-angiogenic properties. Methods In a phase II trial, we examined the efficacy of an eribulin-containing neoadjuvant regimen (eribulin- > doxorubicin plus...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Kristina Fanucci, Eren D. Yeh, Ruichao Shi, Lei Qin, Camden P. Bay, Molly DiLullo, Ashka Patel, McKenna Moore, Zachary T. Herbert, Beth T. Harrison, Faina Nakhlis, Jennifer Bellon, Laura Warren, Jennifer L. Guerriero, Sara M. Tolaney, Meredith Regan, Beth Overmoyer, Steven Van Laere, Filipa Lynce
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMC 2025-09-01
Cyfres:Breast Cancer Research
Pynciau:
Eribulin
Doxorubicin
Cyclophosphamide
Neoadjuvant therapy
HER2-negative
Inflammatory Breast Cancer
Mynediad Ar-lein:https://doi.org/10.1186/s13058-025-02108-4
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg